Abbott Announces Launch of Next-Generation Embolic Protect... (pheral artery disease. The company is co...)

Abbott Announces Launch of Next-Generation Embolic Protection System

Date:6/12/2009

pheral artery disease. The company is committed to making investments in endovascular therapies and educational programs and to designing and conducting endovascular clinical trials.

Abbott's Clinical Program and Leadership in Carotid Clinical Studies

Abbott is the worldwide market leader in carotid artery stenting technology. The Abbott carotid product portfolio provides physicians with multiple carotid stent and embolic protection options: the ACCULINK(R) and the XACT(TM) Carotid Stent Systems, and the ACCUNET(TM) and EMBOSHIELD(R) family of embolic protection systems.

Abbott has the most comprehensive clinical trial programs in studying the benefits of minimally invasive carotid artery stenting. To date, more than 16,000 patients have been enrolled in nine clinical trials evaluating Abbott's carotid stent systems. These include CREST and ACT I, which are randomized, controlled trials designed to understand the benefits of carotid artery stenting in patients at normal risk for surgery; ARCHeR and SECuRITY trials for U.S. Food and Drug Administration (FDA) device approval; and EXACT, CAPTURE, CAPTURE 2 and CHOICE, post-market studies designed to gather real-world clinical information about carotid artery stenting patients.

A March 6, 2009, publication in Circulation: Cardiovascular Interventions, a peer-reviewed journal of the AHA, examines 30-day outcomes from the EXACT and CAPTURE 2 clinical studies. The article concludes that outcomes for carotid artery stenting using Abbott's devices in high-surgical-risk patients under the age of 80 achieved AHA standards in both symptomatic and asymptomatic lesions.

For images of Abbott's carotid stent and embolic protection systems and other information, please visit www.carotidmediakit.com.

About Carotid Artery Disease and Carotid Stenting'/>"/>

1

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition

Post Your Comments:

Abbott Announces Launch of Next-Generation Embolic Protect...(pheral artery disease. The company is co...),Health